Summary
EudraCT Number: 2007-007932-25
Sponsor's Protocol Code Number: 28091
National Competent Authority: France - ANSM 
Clinical Trial Type: EEA CTA
Trial Status: Completed
Date on which this record was first entered in the EudraCT database: 2008-02-22
Link: https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-007932-25/FR/

A. Protocol Information
A.1 Member State Concerned: France - ANSM
A.2 EudraCT number: 2007-007932-25
A.3 Full title of the trial: A phase IIIb randomized open-label study to compare between IVF/ICSI outcomes two  regimen of Cetrotide 0.25 mg used from Day 1 or from Day 7 of the menstrual cycle (Day 0 or Day 6 of stimulation) in polycystic ovarian (PCO) women in ART.
A.3.2 Name or abbreviated title of the trial where available: ATTAC-PCO Study 
A.4.1 Sponsor's protocol code number: 28091
A.7 Trial is part of a Paediatric Investigation Plan: Information not present in EudraCT
A.8 EMA Decision number of Paediatric Investigation Plan: 

B. Sponsor Information
Sponsor 1
B.1.1 Name of Sponsor: Merck Lipha Santé
B.1.3.4	Country: France
B.3.1 and B.3.2	Status of the sponsor: Commercial
B.4 Source(s) of Monetary or Material Support for the clinical trial:
B.4.1 Name of organisation providing support:
B.4.2 Country:
B.5 Contact point designated by the sponsor for further information on the trial
B.5.1 Name of organisation: 
B.5.2 Functional name of contact point: 

D. IMP Identification
D.IMP: 1
D.1.2 and D.1.3 IMP Role: Test
D.2 Status of the IMP to be used in the clinical trial
D.2.1 IMP to be used in the trial has a marketing authorisation: Yes
D.2.1.1.1 Trade name: Cetrotide 0,25 mg poudre et solvant pour solution injectable
D.2.1.1.2 Name of the Marketing Authorisation holder: Serono Europe Limited
D.2.1.2 Country which granted the Marketing Authorisation: European Union
D.2.5 The IMP has been designated in this indication as an orphan drug in the Community: No
D.2.5.1 Orphan drug designation number: 
D.3 Description of the IMP
D.3.4 Pharmaceutical form: Powder and solvent for solution for injection
D.3.4.1 Specific paediatric formulation: Information not present in EudraCT
D.3.7 Routes of administration for this IMP:
Subcutaneous use
D.3.11 The IMP contains an
D.3.11.1 Active substance of chemical origin: Yes
D.3.11.2 Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP): Yes
D.3.11.3 Advanced Therapy IMP (ATIMP): Information not present in EudraCT
D.3.11.3.1 Somatic cell therapy medicinal product: No
D.3.11.3.2 Gene therapy medical product: No
D.3.11.3.3 Tissue Engineered Product: Information not present in EudraCT
D.3.11.3.4 Combination ATIMP (i.e. one involving a medical device): Information not present in EudraCT
D.3.11.3.5 Committee on Advanced therapies (CAT) has issued a classification for this product: Information not present in EudraCT
D.3.11.4 Combination product that includes a device, but does not involve an Advanced Therapy: Information not present in EudraCT
D.3.11.5 Radiopharmaceutical medicinal product: No
D.3.11.6 Immunological medicinal product (such as vaccine, allergen, immune serum): No
D.3.11.7 Plasma derived medicinal product: No
D.3.11.8 Extractive medicinal product: No
D.3.11.9 Recombinant medicinal product: Information not present in EudraCT
D.3.11.10 Medicinal product containing genetically modified organisms: No
D.3.11.11 Herbal medicinal product: No
D.3.11.12 Homeopathic medicinal product: No
D.3.11.13 Another type of medicinal product: Yes
D.3.11.13.1 Other medicinal product type: The IMP is synthesized by using various amino acids as starting material . These compounds are either obtained by chemical
synthesis or origin from plant material or from non-ruminant animal sources.
D.IMP: 2
D.1.2 and D.1.3 IMP Role: Test
D.2 Status of the IMP to be used in the clinical trial
D.2.1 IMP to be used in the trial has a marketing authorisation: Yes
D.2.1.1.1 Trade name: Ovitrelle 250 microgrammes/0,5 ml solution injectable en seringue préremplie
D.2.1.1.2 Name of the Marketing Authorisation holder: Serono Europe Limited
D.2.1.2 Country which granted the Marketing Authorisation: European Union
D.2.5 The IMP has been designated in this indication as an orphan drug in the Community: No
D.2.5.1 Orphan drug designation number: 
D.3 Description of the IMP
D.3.4 Pharmaceutical form: Solution for injection
D.3.4.1 Specific paediatric formulation: Information not present in EudraCT
D.3.7 Routes of administration for this IMP:
Subcutaneous use
D.3.11 The IMP contains an
D.3.11.1 Active substance of chemical origin: No
D.3.11.2 Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP): Yes
D.3.11.3 Advanced Therapy IMP (ATIMP): Information not present in EudraCT
D.3.11.3.1 Somatic cell therapy medicinal product: No
D.3.11.3.2 Gene therapy medical product: No
D.3.11.3.3 Tissue Engineered Product: Information not present in EudraCT
D.3.11.3.4 Combination ATIMP (i.e. one involving a medical device): Information not present in EudraCT
D.3.11.3.5 Committee on Advanced therapies (CAT) has issued a classification for this product: Information not present in EudraCT
D.3.11.4 Combination product that includes a device, but does not involve an Advanced Therapy: Information not present in EudraCT
D.3.11.5 Radiopharmaceutical medicinal product: No
D.3.11.6 Immunological medicinal product (such as vaccine, allergen, immune serum): No
D.3.11.7 Plasma derived medicinal product: No
D.3.11.8 Extractive medicinal product: No
D.3.11.9 Recombinant medicinal product: Information not present in EudraCT
D.3.11.10 Medicinal product containing genetically modified organisms: Information not present in EudraCT
D.3.11.11 Herbal medicinal product: No
D.3.11.12 Homeopathic medicinal product: No
D.3.11.13 Another type of medicinal product: No

D.8 Information on Placebo

E. General Information on the Trial
E.1 Medical condition or disease under investigation
E.1.1 Medical condition(s) being investigated: ﻿Prevention of premature ovulation in polycystic ovarian women undergoing a controlled ovarian stimulation, followed by oocyte pick-up and assisted reproductive techniques. 	 

MedDRA Classification
E.1.3 Condition being studied is a rare disease: No
E.2 Objective of the trial
E.2.1 Main objective of the trial: To compare the hormonal level changes on the releasing day (day of r-hCG administration) induced by Cetrotide 0.25 mg/d started on Day 1 (Goup A: D1) with Cetrotide 0.25 started  on Day 7 (Goup B: D7) of the menstrual cycle (Day 0 (S0) or Day 6 (S6) of stimulation) in polycystic ovarian (PCO) subjects undergoing IVF/ICSI procedures.
E.2.2 Secondary objectives of the trial: To compare the hormonal changes during the stimulation induced by Cetrotide in A and B Groups
To assess by ultrasound scans (US) the follicular development induced by Cetrotidein A and B Groups
To assess biological and clinical outcomes induced by Cetrotide in A and B Groups
To monitor safety of Cetrotide in A and B Groups

E.2.3 Trial contains a sub-study: No
E.3 Principal inclusion criteria: -	Women with PCO or PCOS according to the revised 2003 Rotterdam Consensus 
-	Suitable for IVF/ICSI, undergoing first or second attempt 
-	18-35 years old, Body Mass Index (BMI)  32, non smoking 
-	Normal FSH value (< 10 IU/L) and AMH value (> 1,5 ng/ml) on day 3 of spontaneous cycle within 3 months prior to the trial 
-	No history of active genito-urinary infection
-	Normal thyroid function (or adequate substitution for at least 3 months).
-	Negative cervical Papanicolau test within the last 12 months prior to study entry.
-	No gonadotropins, for at least 3 months prior to the trial
-	No metformin therapy 1 month prior to the trial
-	Subject is willing and able to participate in the trial and has provided written, informed consent.

E.4 Principal exclusion criteria: -	Ongoing pregnancy, any pregnancy within 3 months prior to study entry, or any contraindication to pregnancy or carrying pregnancy to term
-	Uterine malformation, diethylstilbestrol syndrome, synechia
-	Women with WHO type I or III anovulation
-	Women with hyperprolactinemia
-	More than 2 recurrent miscarriages (early or late, and for any reasons)
-	Known infection with Human Immunodeficiency Virus (HIV), Hepatitis B or C virus, for subject or partner
-	Abnormal gynaecological bleeding of undetermined origin
-	History of major thromboembolic disease 
-	Endometriosis (grade III or IV)
-	Presence or history of malignant tumours and related treatment 
-	Known case of tumours of the hypothalamus or pituitary gland
-	Clinically significant systemic disease or clinically significant abnormal haematology, chemistry, or urinalysis results at screening
-	Known allergic reaction or hypersensitivity to Cetrotide or Ovid[t]rel[le]®
-	Any active substance abuse or history of drug, medication or alcohol abuse in the past 5 years
-	Participation in another clinical trial within 3 months prior to study entry 

E.5 End points
E.5.1 Primary end point(s): Estradiol (E2) level on the releasing day (day of r-hCG administration) in A and B Groups.
E.6 and E.7 Scope of the trial
E.6 Scope of the Trial
E.6.1 Diagnosis: No
E.6.2 Prophylaxis: No
E.6.3 Therapy: No
E.6.4 Safety: Yes
E.6.5 Efficacy: Yes
E.6.6 Pharmacokinetic: No
E.6.7 Pharmacodynamic: No
E.6.8 Bioequivalence: No
E.6.9 Dose response: No
E.6.10 Pharmacogenetic: No
E.6.11 Pharmacogenomic: No
E.6.12 Pharmacoeconomic: No
E.6.13 Others: No
E.7 Trial type and phase 
E.7.1 Human pharmacology (Phase I): No
E.7.1.1 First administration to humans: No
E.7.1.2 Bioequivalence study: No
E.7.1.3 Other: No
E.7.1.3.1 Other trial type description: 
E.7.2 Therapeutic exploratory (Phase II): No
E.7.3 Therapeutic confirmatory (Phase III): Yes
E.7.4 Therapeutic use (Phase IV): No
E.8 Design of the trial
E.8.1 Controlled: Yes
E.8.1.1 Randomised: Yes
E.8.1.2 Open: Yes
E.8.1.3 Single blind: No
E.8.1.4 Double blind: No
E.8.1.5 Parallel group: Yes
E.8.1.6 Cross over: No
E.8.1.7 Other: No
E.8.2 Comparator of controlled trial
E.8.2.1 Other medicinal product(s): No
E.8.2.2 Placebo: No
E.8.2.3 Other: Yes
E.8.2.3.1 Comparator description: Another regimen of administration of Cetrotide
E.8.3 The trial involves single site in the Member State concerned: No
E.8.4 The trial involves multiple sites in the Member State concerned: Yes
E.8.4.1 Number of sites anticipated in Member State concerned: 2
E.8.5 The trial involves multiple Member States: No
E.8.6 Trial involving sites outside the EEA
E.8.6.1 Trial being conducted both within and outside the EEA: No
E.8.6.2 Trial being conducted completely outside of the EEA: Information not present in EudraCT
E.8.7 Trial has a data monitoring committee: No
E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial: The date of the final database lock.
E.8.9 Initial estimate of the duration of the trial
E.8.9.1 In the Member State concerned years: 2
E.8.9.1 In the Member State concerned months: 
E.8.9.1 In the Member State concerned days: 

F. Population of Trial Subjects
F.1 Age Range
F.1.1 Trial has subjects under 18: No
F.1.1.1 In Utero: Information not present in EudraCT
F.1.1.2 Preterm newborn infants (up to gestational age < 37 weeks): Information not present in EudraCT
F.1.1.3 Newborns (0-27 days): Information not present in EudraCT
F.1.1.4 Infants and toddlers (28 days-23 months): Information not present in EudraCT
F.1.1.5 Children (2-11years): Information not present in EudraCT
F.1.1.6 Adolescents (12-17 years): Information not present in EudraCT
F.1.2 Adults (18-64 years): Yes
F.1.3 Elderly (>=65 years): No
F.2 Gender
F.2.1 Female: Yes
F.2.2 Male: No
F.3 Group of trial subjects
F.3.1 Healthy volunteers: No
F.3.2 Patients: Yes
F.3.3 Specific vulnerable populations: Yes
F.3.3.1 Women of childbearing potential not using contraception : Yes
F.3.3.2 Women of child-bearing potential using contraception: No
F.3.3.3 Pregnant women: No
F.3.3.4 Nursing women: No
F.3.3.5 Emergency situation: No
F.3.3.6 Subjects incapable of giving consent personally: No
F.3.3.7 Others: No
F.4 Planned number of subjects to be included
F.4.1 In the member state: 210
F.4.2 For a multinational trial

G. Investigator Networks to be involved in the Trial


N. Review by the Competent Authority or Ethics Committee in the country concerned
N. Competent Authority Decision: Authorised
N. Date of Competent Authority Decision: 2008-03-12
N. Ethics Committee Opinion of the trial application: Favourable
N. Ethics Committee Opinion: Reason(s) for unfavourable opinion:
N. Date of Ethics Committee Opinion: 2008-05-07

P. End of Trial
P. End of Trial Status: Completed
P. Date of the global end of the trial: 2012-02-28

